A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE

Inclusion Criteria: * Adult patients ≥ 18 years at AML diagnosis * Patients that started gilteritinib during ATU and post-ATU period from 19th March 2019 to 30th March2021 * Patients diagnosed with refractory or relapsed AML as defined by the World Health Organization (WHO) Classification * Patients with FLT3 genetic testing performed at diagnosis and/or at R/R (if available) * Gilteritinib with or without other drug (chemotherapy, hypomethylating agent, hydroxyurea, etc.) Exclusion Criteria: * Newly diagnosed AML patients * Participant opposed to the collection and analysis of their medical data * Prescription of gilteritinib out of the scope of its marketing authorisation approval such as post HSCT maintenance in patients in first complete remission after intensive chemotherapy * persons placed in curatorship,guardianship or guardianship orders